CNV Dopamine

Pricing Availability   Qty
Description: Caged dopamine; photolysed by UV light
Purity: ≥98% (HPLC)
Literature (2)

Biological Activity for CNV Dopamine

CNV Dopamine is a carboxynitroveratryl (CNV)-caged dopamine (Cat. No. 3548); releases dopamine upon ultraviolet light stimulation (365 nm). Induces dopaminergic currents upon photolysis in brain slices expressing wild-type or GFP-labeled D2 receptors. Displays no decrease in current (rundown) with UV light flash duration of up to 100 ms. Pharmacologically inactive prior to photolysis.

Technical Data for CNV Dopamine

M. Wt 392.36
Formula C18H20N2O8
Storage Store at -20°C
Purity ≥98% (HPLC)
Smiles OC1=CC(CCN)=CC=C1OC(C(O)=O)C2=CC(OC)=C(OC)C=C2[N+]([O-])=O.NCCC3=CC=C(O)C(OC(C(O)=O)C4=CC(OC)=C(OC)C=C4[N+]([O-])=O)=C3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for CNV Dopamine

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 39.24 100
water 19.62 50

Preparing Stock Solutions for CNV Dopamine

The following data is based on the product molecular weight 392.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.55 mL 12.74 mL 25.49 mL
5 mM 0.51 mL 2.55 mL 5.1 mL
10 mM 0.25 mL 1.27 mL 2.55 mL
50 mM 0.05 mL 0.25 mL 0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for CNV Dopamine

References are publications that support the biological activity of the product.

Robinson et al (2017) Desensitized D2 autoreceptors are resistant to trafficking. Sci.Rep. 7 4379 PMID: 28663556

If you know of a relevant reference for CNV Dopamine, please let us know.

Keywords: CNV Dopamine, CNV Dopamine supplier, caged, dopamine, agonists, receptor, Carboxynitroveratryl, CNV, photolysis, Caged, Dopamine, Compounds, Non-selective, 6354, Tocris Bioscience

Citations for CNV Dopamine

Citations are publications that use Tocris products.

Currently there are no citations for CNV Dopamine. Do you know of a great paper that uses CNV Dopamine from Tocris? Please let us know.

Reviews for CNV Dopamine

There are currently no reviews for this product. Be the first to review CNV Dopamine and earn rewards!

Have you used CNV Dopamine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.